Disentangling the relationship between cancer mortality and COVID-19 Authors: Chelsea L. Hansen^{1,2,3}, Cécile Viboud¹, Lone Simonsen^{1,2} ¹Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA. 20892 ²PandemiX Center, Dept of Science & Environment, Roskilde University, Denmark ³Brotman Baty Institute, University of Washington, Seattle, WA Word count: 5480 (including headings)

25

26

27

28

29

30

31

32

33 34

35

36

37

38

39

40 41

42

43

44

45

46

47

48 49

50

51

52

53

54

55

56

57

58

2

Abstract (368 words) Several countries have reported that deaths with a primary code of cancer did not rise during COVID-19 pandemic waves compared to baseline pre-pandemic levels. This is in apparent conflict with findings from cohort studies where cancer has been identified as a risk factor for COVID-19 mortality. Here we further elucidate the relationship between cancer mortality and COVID-19 on a population level in the US by testing the impact of death certificate coding changes during the pandemic and leveraging heterogeneity in pandemic intensity across US states. We computed excess mortality from weekly deaths during 2014-2020 nationally and for three states with distinct COVID-19 wave timing (NY, TX, and CA). We compared pandemicrelated mortality patterns from underlying and multiple causes (MC) death data for six types of cancer and high-risk chronic conditions such as diabetes and Alzheimer's. Any coding change should be captured in MC data. Nationally in 2020, we found only modest excess MC cancer mortality (~12,000 deaths), representing a 2% elevation over baseline. Mortality elevation was measurably higher for less deadly cancers (breast, colorectal, and hematologic, 2-5%) than cancers with a poor 5-year survival (lung and pancreatic, 0-1%). In comparison, there was substantial elevation in MC deaths from diabetes (39%) and Alzheimer's (31%). Homing in on the intense spring 2020 COVID-19 wave in NY, mortality elevation was 2-15% for cancer and 126% and 55% for diabetes and Alzheimer's, respectively. Simulations based on a demographic model indicate that differences in life expectancy for these conditions, along with the age and size of the at-risk populations, largely explain the observed differences in excess mortality during the COVID-19 pandemic. In conclusion, we found limited elevation in cancer mortality during COVID-19 waves, even after considering coding changes. Our demographic model predicted low expected excess mortality in populations living with certain types of cancer, even if cancer is a risk factor for COVID-19 fatality risk, due to competing mortality risk. We also find a moderate increase in excess mortality from blood cancers, aligned with other types of observational studies. While our study concentrates on the immediate consequences of the COVID-19 pandemic on cancer mortality, further research should consider the pandemic impact on hospitalizations, delayed diagnosis/treatment and risk of Long COVID in cancer patients.

Introduction

The dominant risk factors for COVID-19 mortality have consistently been shown to be advanced age, male gender and certain chronic diseases such as diabetes, obesity and heart disease (Chavez-MacGregor et al., 2022; Rüthrich et al., 2021; Williamson et al., 2020). Cancer has also been identified as a high-risk condition based on case-control and cohort studies, although these studies have provided conflicting results. In a large cohort study of ~500,000 COVID-19 inpatients, only cancer patients under recent treatment were at increased risk of COVID-19 related deaths (OR=1.7) relative to non-cancer patients (Chavez-MacGregor et al., 2022). Conversely, a smaller European study of 3,000 COVID-19 inpatients found that cancer was not a risk factor (Rüthrich et al., 2021), as did an international, multicenter study of 4,000 confirmed COVID-19 inpatients (Raad et al., 2023). More recently a meta-analysis of 35 studies from Europe, North America, and Asia found a 2-fold increased risk of COVID-19 mortality among cancer patients (Di Felice et al., 2022). Similarly, a large analysis from the UK found that the risk of COVID-19 mortality for cancer patients had declined over the course of the pandemic but remained 2.5 times higher than for non-cancer patients into 2022 (Starkey et al., 2023). Taken together, such observational studies provide a mixed picture of cancer as a COVID-19 mortality risk factor, with several studies reporting that controlling for other important factors such as age is a challenge. Further, cancer is often considered as a single disease category despite the diversity of conditions and patients represented.

Further evidence for the relationship between cancer and COVID-19 comes from population-level analysis of vital statistics. A recent US study showed no elevation in cancer deaths concomitant with COVID-19 waves, in stark contrast to mortality from other chronic diseases (W.-E. Lee et al., 2023). Several other countries, including Sweden, Italy, Latvia, Brazil, England and Wales also observed stable or decreasing cancer mortality during the first year of the pandemic (Alicandro et al., 2023; Fernandes et al., 2021; Gobiņa et al., 2022; Grande et al., 2022; Kontopantelis et al., 2022; Lundberg et al., 2023). Further, a study of 240,000 cancer patients in Belgium found a 33% rise in mortality in April 2020, but concluded that this was no different from the excess mortality observed in the general population (Silversmit et al., 2021). These findings raise the question of the true relationship between cancer and COVID-19.

The relationship between these two diseases could operate via multiple biological mechanisms, where immunosuppression in cancer patients could increase susceptibility to SARS-CoV-2 infection and/or risk of severe clinical outcome upon infection. Conversely, immunosuppression could be seen as a protective factor in the face of a severe respiratory infection that over stimulates the immune system – the immune incompetence rescue hypothesis. (Reichert 2004). This hypothesis was put forward to explain the lack of elevation in underlying cancer mortality during the 1968 influenza pandemic and severe influenza epidemics, a departure from patterns seen for other high-risk conditions such as heart disease and diabetes (Reichert 2004). A further mechanism that could affect the observed relationship between cancer deaths and COVID-19 is changing guidelines for establishing the primary cause of death. Coding guidelines evolved throughout the pandemic as testing for SARS-CoV-2 infection became more widespread, which presumably affected vital statistics studies.

100 101 To further elucidate the relationship between cancer mortality and COVID-19 on a population 102 level, we analyzed US vital statistics in detail to understand the potential role of coding changes 103 during the pandemic and explored putative differences in mortality patterns between different 104 types of cancer. The US provides a particularly useful case study as the timing of COVID-19 105 waves varied considerably between states, so that elevations in cancer deaths, should they 106 exist, should also be heterogeneous. For context, we also assessed mortality patterns for other 107 chronic conditions such as diabetes, ischemic heart disease (IHD), kidney disease, and 108 Alzheimer's, for which the association with COVID-19 is less debated. 109 **Results** 110 Establishing patterns and timing of COVID-19 related deaths 111 We obtained individual ICD-10 coded death certificate data from the US for the period January 112 1, 2014, to December 31, 2020. We compiled time series by week, state, and cause of death, 113 for underlying cause (UC) and for multiple-cause (MC, any mention on death certificate) 114 mortality. We considered 10 causes of death, including diabetes, Alzheimer's disease, ischemic 115 heart disease (IHD), kidney disease, and 6 types of cancer (all-cause cancer, colorectal, breast, 116 pancreatic, lung, and hematological; see Table 1 and Appendix 1 - Table 1 for a list of disease 117 codes). We chose these types of cancer to illustrate conditions for which the 5- year survival 118 rate is low (13% and 25%, respectively, for pancreatic and lung cancers) and high (65% and 119 91%, respectively, for colorectal and breast cancers) (National Cancer Institute, n.d.). 120 Hematological cancer (67% 5-year survival rate) was included because it has been singled out 121 as a risk factor in several previous studies (Chavez-MacGregor et al., 2022; X. Han et al., 2022; 122 Rüthrich et al., 2021; Williamson et al., 2020). To compare mortality patterns with the timing of 123 COVID-19 pandemic waves, we accessed national and state counts of reported COVID-19 124 cases from the Centers for Disease Control and Prevention (CDC)(Centers for Disease Control 125 and Prevention, 2022). 126 In national data, time series of COVID-19-coded death certificates (both UC and MC) tracked 127 with the temporal patterns of laboratory-confirmed COVID-19 cases (Figure 1), revealing three 128 distinct COVID-19 waves: a spring wave peaking on April 12, 2020, a smaller summer wave 129 peaking on July 26, 2020, and a large winter wave that had not yet peaked by the end of the 130 study in December 2020. This correspondence between COVID-19 case and death activity 131 represents a "signature" mortality pattern of COVID-19. 132 In state-level data, different states experienced variable timing, intensity and number of COVID-133 19 waves during 2020. To focus on periods with substantial COVID-19 activity and explore the 134 association with cancer, we identified three large US states with unique, well-defined waves 135 (Figure 1). New York (NY) state experienced a large, early wave in March-May 2020, based on 136 recorded COVID-19 cases and deaths and high seroprevalence of SARS-CoV-2 antibodies in 137 New York City in this period (over 20% (Stadlbauer et al., 2021)). Meanwhile, California (CA)

experienced a large COVID-19 wave at the end of the year and had only little activity during the

139 spring and summer. Finally, Texas (TX) had two large waves; one during late summer, followed 140 by one in winter 2020. 141 National patterns in excess mortality from cancer 142 Similar to other influenza and COVID-19 population-level mortality studies (W.-E. Lee et al., 143 2023), we established a weekly baseline model for expected mortality in the absence of 144 pandemic activity by modeling time trends and seasonality in pre-pandemic data and letting the 145 model run forward during the pandemic (see Methods). Each cause of death (UC and MC) and 146 geography was modeled separately. We then computed excess mortality as the difference 147 between observed deaths and the model-predicted baseline. We summed weekly estimates to 148 calculate excess mortality for the full pandemic period and during each of the 3 waves (see 149 Methods). In addition to these absolute effects of the pandemic on mortality, we also calculated 150 the relative effects by dividing excess mortality by baseline mortality (see Methods). Nationally, we found a drop in UC cancer deaths during spring 2020 (Figure 2, panel a; Table 151 152 2), although the drop was not statistically significant. A similar non-significant decline was also 153 seen for specific cancer types (Figure 2, panels b-c; Appendix 1 - Figure 1, panels a;f-j). We 154 also saw that pre-pandemic mortality trends for each cancer type continued unabated during the 155 first pandemic year. We reasoned that the drop in UC cancer deaths seen at the start of the 156 pandemic could be evidence of a modest harvesting effect or alternatively could be due to 157 changes in coding practices. If a death occurred in a cancer patient with COVID-19, the death 158 could be coded with COVID-19 as the underlying cause of death and could explain the 159 observed drop. We turned to MC mortality to resolve this question. 160 Time series of MC cancer mortality (any mention of any cancer code) showed a significant 161 increase in all three waves (Figure 2, panel a; Appendix 1 - Table 2). A similar pattern was seen 162 in MC time series for colorectal (Figure 2, panel h), breast (Appendix 1 - Figure 1, panel i), and 163 hematological cancer (Appendix 1 - Figure 1, panel j). However, the total excess mortality was 164 modest with 12,000 excess cancer deaths in 2020, representing a statistically significant 2% 165 elevation over baseline (Table 2). The largest relative increase in MC mortality was observed in 166 hematological cancer at 5% (statistically significant, 3100 excess deaths). No excess in MC 167 mortality was seen for the two deadliest cancers, pancreatic cancer (Figure 2, panel f) and lung 168 cancer (Appendix 1 - Figure 1, panel g). 169 National patterns in deaths due to other chronic conditions 170 We considered diabetes and Alzheimer's as "positive controls" as they are also considered COVID-19 risk factors and can illustrate associations between excess mortality from chronic 171 172 conditions and COVID-19 on a population level. Diabetes provides a particularly useful 173 comparator for cancer as the mean age at death is similar (~72 years, Table 1) and because 174 few individuals live in a nursing home (Appendix 1 - Supplemental Methods). Mortality time 175 series from UC and MC diabetes and Alzheimer's were highly correlated with COVID-19 activity,

with statistically significant mortality elevation synchronous with pandemic wave activity (Figure

2 b-c; Appendix 1 - Figures 2-5). For diabetes, we measured an excess of 11,400 and 85,700

176

178 deaths (UC and MC, respectively), corresponding to an elevation of 17% and 39% over baseline 179 level mortality (Table 2). For Alzheimer's, we estimated 18,500 and 32,200 excess deaths, 180 corresponding to 21% and 31% elevation over baseline, respectively. Pandemic-related excess 181 mortality was also seen for IHD and kidney disease (see supplement for estimates, Appendix 1 -182 Table 2). 183 State-level patterns in excess mortality 184 Similar to cancer patterns in national level data, none of the studied states had notable 185 increases in UC cancer mortality, while there was a modest, non-significant increase in MC 186 cancer mortality (Figures 3-5; Appendix 1 - Figures 6-8). The largest mortality increase was 187 seen in NY during the spring wave, with an 8% rise in MC cancer mortality above the model 188 baseline (Table 2; Appendix 1 - Table 3). The magnitude of the increase seen during the spring 189 wave varied by cancer type, with minimal increases seen in pancreatic and lung cancers (≤2%) 190 and higher increases in colorectal, hematological, and breast cancers (8, 13, and 15% 191 respectively). For comparison, there was a statistically significant rise in Alzheimer's and 192 diabetes deaths during this wave by 55% and 126%. 193 In CA and TX, mortality fluctuations were less pronounced than in NY, coinciding with less 194 intense COVID-19 waves, and this was seen across all conditions. MC excess mortality estimates remained within +/-6% of baseline levels for cancers, irrespective of the type of 195 196 cancer and pandemic wave, except for a 12% elevation in hematological cancer (MC) during the 197 summer wave in Texas. None of these elevations were statistically significant. In comparison, 198 there was significant excess mortality elevation for both Alzheimer's and diabetes deaths 199 (range, 25-49% in the CA winter wave, and 65-76% in the TX summer wave, Appendix 1-200 Tables 4-5). 201 Mortality projections under the null hypothesis that cancer in and of itself is not a risk factor for 202 COVID-19 mortality 203 Two main factors could drive cancer mortality patterns during COVID-19, namely the age of the 204 population living with cancer (since age is such a pronounced risk factor for COVID-19), and the 205 life expectancy under cancer diagnosis. These factors would operate irrespective of the true 206 biological relationship between SARS-CoV-2 infection, severity, and cancer. 207 To test the impact of these factors on observed excess mortality patterns and assess whether 208 these factors alone could explain differences in excess mortality between chronic conditions, we 209 designed a simple demographic model of COVID-19 mortality for individuals with chronic 210 conditions. The model projected excess mortality during the pandemic under the null hypothesis 211 that the chronic condition was not in and of itself a risk factor for COVID-19 mortality, with only 212 the demography of the population living with the disease (namely, age, size and baseline risk of 213 death) affecting excess mortality. In the demographic model, we first estimated the number of 214 expected COVID-19 infections among persons with a certain condition, by multiplying the

estimated number of US individuals living with the condition by the reported SARS-CoV-2

seroprevalence at the end of our study period (December 2020). We focused on

215

seroprevalence among individuals ≥65 years, the most relevant age group for the conditions we considered. We then multiplied the estimated number of SARS-CoV-2 infections by an age-adjusted infection-fatality ratio (IFR) for SARS-CoV-2 (COVID-19 Forecasting Team, 2022). This gave an estimate of COVID-19-related deaths, or excess deaths, for a given condition. We divided our excess death estimate by the total deaths for that condition in 2019 to estimate a percent elevation over baseline (see Methods). We repeated this analysis for each cancer type, diabetes, Alzheimer's, IHD, and kidney disease. In addition to the null hypothesis, we also projected an alternative hypothesis of a biological association, assuming that a given chronic condition would raise the risk of COVID-19 mortality (via the infection fatality ratio) by a factor 2. We compared these modeled expectations for the null and alternative hypotheses with the observed excess mortality in 2020, focusing on MC as the outcome (Table 2).

Under the null hypothesis we projected a 7% elevation in all cancer deaths over the 2019 baseline (Table 3). For hematological cancers and particularly deadly cancers such as pancreatic and lung, we projected only a 1-2% elevation in mortality, in part driven by the high competing risk of death from these cancers (short life expectancy) and the small size of the population-at-risk. For colorectal and breast cancers, we projected a 6% and 14% elevation in mortality, in part driven by the lower risk of death from these cancers (longer life expectancy). Under the alternative hypothesis that cancer doubled the COVID-19 infection fatality rate (IFR), we projected a 13% elevation in total cancer mortality, 2% in pancreatic- and 28% in breast cancer. In empirical national MC mortality data, we observed a 0-3% elevation over baseline for all the non-hematological cancers and 5% for hematological cancers, more consistent with the null hypothesis. We note, however, that for the large spring wave in NY state the rise in cancers was closer to that projected under the assumption of a relative risk of 2.

We repeated this analysis for diabetes, Alzheimer's, IHD, and kidney disease mortality (Table 3; Appendix 1 - Table 6). For diabetes we projected a 28% elevation over baseline based on the age distribution and substantial size of the population-at-risk alone. In fact, we observed a 39% elevation over baseline in national US data. For Alzheimer's we projected a 46% increase over baseline, while we found a 31% increase in national US mortality data. Similarly, for IHD and kidney disease, the magnitude of the excess mortality rise projected under the demographic model was higher than for cancer and consistent with observations (Appendix 1- Table 6). These projections support the idea that demography alone (age, size, and baseline mortality of the population living with each of these conditions) can explain much of the differences in absolute and relative mortality elevations seen during the pandemic across conditions like cancer, diabetes, and Alzheimer.

Discussion

Cancer is generally thought of as a risk factor for severe COVID-19 outcomes, yet observational studies have produced conflicting evidence. With recent availability of more detailed US vital statistics data, we used statistical time series approaches to generate excess mortality estimates for multiple cause of death data, different types of cancer, and several geographic locations. We accounted for potential changes in coding practices during the pandemic, for instance capturing a COVID-19 patient with cancer whose death may have been coded as a

primary COVID-19 death and not a cancer death. Based on multiple cause of death data, we estimated 12,000 national COVID-19-related excess cancer deaths, which aligns well with reporting on death certificate data, where 13,400 deaths are ascribed to COVID-19 in cancer patients (Appendix 1 - Figure 9). Yet these deaths only represent a 2% elevation over the expected baseline cancer mortality. Percent mortality elevation was measurably higher for less deadly cancers (breast and colorectal) than cancers with a poor 5-year survival (lung and pancreatic). Consistent with other studies (Chavez-MacGregor et al., 2022; S. Han et al., 2022; Rüthrich et al., 2021; Williamson et al., 2020), we found that the largest mortality increase for specific cancer types was seen in hematological cancers with a 5% elevation over baseline.

In contrast to cancer, we observed substantial COVID-19-related excess mortality for diabetes and Alzheimer's, temporally consistent with the three-wave "signature" pattern observed in reported COVID-19 cases and deaths. To investigate whether demographic differences in underlying patient populations (age distribution, population size, and baseline risk of death due to underlying condition) could explain differences in excess mortality during the pandemic, we ran a simple demographic model for each condition – first assuming the condition in and of itself was not a risk factor for COVID-19-related mortality (null hypothesis). The results of these projections were consistent with observed excess mortality patterns; specifically, we did not expect to see large increases in cancer deaths compared to these other chronic conditions. These projections also illustrate the importance of competing risks, where the risk of cancer death predominates over the risk of COVID-19 death. This is exacerbated for cancers with the lowest survival; for instance, for pancreatic cancer, under the null hypothesis we would expect a <1% risk of mortality from COVID-19 in 2020 (assuming a 9% attack rate and 2.6% IFR, Appendix 1 - Table 7). In contrast, the 2019 baseline risk of death for pancreatic cancer itself is 43.5% (ratio of deaths to population-at-risk = 1:2.3, Table 3). Even if pancreatic cancer had in fact doubled the risk of dying of COVID-19 (IFR = 5.2), we would not expect to see more than a 1% excess mortality elevation during the pandemic (Table 3), due to the high baseline level mortality associated with this disease. On the other hand, conditions with a lower baseline level mortality, such as diabetes (<1% baseline risk of death), are more sensitive to COVID-19 driven elevations in mortality.

Our study rules out the immune incompetence rescue hypothesis that was raised in a 2004 paper on excess mortality patterns during influenza seasons (Reichert et al 2004). Similarly, the possibility that infectious disease mortality risk is modulated by immune competence has been put forward to explain the extreme mortality in young healthy adults in the 1918 pandemic (Short et al., 2018). In the 2004 study, cancer deaths did not increase during the 1968 influenza pandemic as it did for other risk conditions, leading the authors to propose that immunosuppressive cancer treatment could mitigate an aberrant immune response to pandemic influenza infection. However, observational studies have consistently found the opposite to be the case for COVID-19 infection in patients with hematological cancers. These patients have twice the risk of dying compared to patients without cancer, likely due to the immunosuppression associated with their malignancy and treatment (X. Han et al., 2022; Starkey et al., 2023; Williamson et al., 2020). Under the immune incompetence rescue hypothesis, one would have expected the opposite – that hematological cancers would have lowest excess mortality of all cancers. Our analysis of empirical vital statistics reveals instead

that hematologic cancers were the most impacted by the pandemic, relative to other types of cancer, with a percent elevation over baseline most pronounced in states that were hit intensely like New York.

Nationally, the observed excess mortality for non-hematological cancers was lower than that expected under our demographic model, even under the null hypothesis of no biological association between non-hematologic cancers and COVID-19. The null hypothesis may still be valid as our analysis ignores any behavioral effects associated with the pandemic. It is conceivable that cancer patients may have shielded themselves from COVID-19 more than the average person or even other persons with chronic diseases in 2020. Our projections assume an average risk of infection for a typical individual over 65 years as there is no serologic data for specific clinical population subgroups (of any age). If shielding was high among cancer patients, our projections of cancer excess mortality during the pandemic would be inflated, potentially explaining the disconnect with observations. Retrospective serologic analysis of banked sera from the first year of the pandemic, broken down by underlying comorbidities, may shed light on whether infection risk may have varied by chronic condition.

State-level mortality patterns can potentially provide indirect insights on the question of shielding from exposure to SARS-CoV-2. Because NY experienced the earliest and most intense COVID-19 wave of the US, with 25% of the population infected in Spring 2020 (Centers for Disease Control and Prevention., 2023), and because social distancing did not come into effect until March 2020, shielding would have had a more limited impact there than in other states. Thus, a biological relationship between cancer and COVID-19 would have been most dramatic in NY in spring 2020. Indeed, cancer excess mortality was exacerbated in NY, including an 8-15% increase in colorectal and breast cancer mortality. Yet these increases are still aligned with the projections from our demographic model under the null hypothesis. The absence of excess mortality in pancreatic and lung cancer in NY (0% and 1% over baseline) are, as discussed above, still consistent with what would be expected under a high competing risk situation.

Most vital statistics studies focused on the COVID-19 pandemic have relied on underlying cause-specific deaths, which are prone to changes in coding practices. Our initial hypothesis going into this work was that coding changes associated with a better recognition of the impact of SARS-CoV-2 led to an underestimation of excess mortality from cancer, affecting our perception of the relationship between cancer and COVID-19. We certainly found an effect of coding changes, where for instance a drop in excess mortality in underlying cancer deaths turned into an increase in any-listed cancer deaths, particularly in the first COVID-19 pandemic wave. The impact of coding changes was also seen in mortality from other chronic conditions but was particularly important for cancer. Yet both the absolute and relative excess mortality elevation remained modest for cancer, even after adjustment for coding changes, leading us to consider additional mechanisms such as the competing risk hypothesis.

Our study is subject to limitations. Given uncertainty in SARS-CoV-2 attack-rates and the age distribution and size of the population-at-risk for all studied conditions, our demographic model projections are not an exact tool to titrate excess mortality nor the relative risk associated with each condition. Our model merely serves as an illustration of the role of demography and

competing risks. Further, we did not study the potential long-term consequences of the pandemic on cancer care, which includes avoidance of the health care system for diagnosis or treatment. We did not see any delayed pandemic effect on mortality from pancreatic cancer, which may have manifested in 2020 given the very low survival rate of this cancer (Lemanska et al., 2023), but we cannot rule out longer-term effects on breast or colorectal cancers that would not be seen until 2021 or later (Doan et al., 2023; Han et al., 2023; Haribhai et al., 2023; R. Lee et al., 2023; Nascimento de Lima et al., 2023; Nickson et al., 2023; Nonboe et al., 2023; Tope et al., 2023). Additional years of data will be important to evaluate such effects. Additional years of data will also be important for assessing the impact of vaccination on the relationship between cancer and COVID-19; there is evidence that vaccines may be less immunogenic in patients with cancer compared to those without (Seneviratne et al., 2022). Another limitation of our study is the reliance on mortality as an outcome, while it may be important to consider the risk of COVID-19-related hospitalization and morbidity, and Long COVID in cancer patients. A small US study reported that 60% of cancer patients suffered Long COVID symptoms (Dagher et al., 2023). Future analyses using hospitalization data and electronic medical records may provide additional insights on how different cancer stages or other comorbidities may contribute to increased risk of severe COVID-19 outcomes. Lastly, a few methodological limitations are worth raising. Though it was important to assess excess mortality in state level data because of asynchrony in pandemic waves, confidence intervals in state-level estimates were large, particularly for specific types of cancers, affecting significance levels. Lastly, our study is a timetrend analysis and - similar to cohort and case-control studies - correlation does not necessarily imply causation. However, the intensity and brevity of COVID-19 pandemic waves in space and time lends support to our analyses.

Conclusion

342

343

344

345

346

347

348

349

350

351

352

353

354

355 356

357

358

359

360

361

362

363 364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

Our detailed excess mortality study considered six cancer types and found that there is at most a modest elevation in cancer mortality during the COVID-19 pandemic in the US. Our results demonstrate the importance of considering multiple-causes-of-death records to accurately reflect changes in coding practices associated with the emergence of a new pathogen. In contrast to earlier studies, we propose that lack of excess cancer mortality during the COVID-19 pandemic reflects the competing mortality risk from cancer (especially for pancreatic and lung cancers) itself rather than protection conferred from immunosuppression. We note the more pronounced elevation in mortality from hematological cancers during the pandemic, compared to other cancers, which aligns with a particular group of cancer patients singled out in several cohort studies. Future research on the relationship between COVID-19 and cancer should concentrate on different outcomes, such as excess hospitalizations, Long COVID, changes in screening practices during COVID-19, and longer-term patterns in cancer mortality.

Materials and Methods

Data sources

US National vital statistics.

We fitted national and state-level models for each mortality outcome from January 19, 2014, to March 1, 2020, and projected the baseline forward until December 6, 2020, the last complete

week of smoothed mortality data.

We first calculated the number of expected COVID-19 infections among persons living with a certain chronic condition, by multiplying the estimated number of individuals living with the

481

491

492

Cécile Viboud: http://orcid.org/0000-0003-3243-4711 Lone Simonsen: http://orcid.org/0000-0003-1535-8526 Data availability

493

- 494 Individual-level mortality data were obtained from the National Center for Healthcare Statistics.
- 495 These data are not publicly available due to privacy concerns, but descriptive characteristics
- have been summarized in Table 1 and Appendix Table 1. The excess mortality models in this 496
- 497 paper use mortality data aggregated by week and US state. These data (with values <10
- 498 suppressed), along with the model code, have been posted to the following public GitHub
- 499 repository: https://github.com/chelsea-hansen/Disentangling-the-relationship-between-cancer-
- 500 mortality-and-COVID-19
- 501 Weekly, state-level data on recorded COVID-19 cases and deaths are publicly available. Data
- were downloaded from the following link: https://data.cdc.gov/Case-Surveillance/Weekly-United-502
- States-COVID-19-Cases-and-Deaths-by-/pwn4-m3yp and have also been posted as a .csv file 503
- 504 to the GitHub repository referenced above.
- 505 Disclaimer
- 506 This article represents the views of the authors and not necessarily those of the National
- 507 Institutes of Health or the US government.
- 508 References

516

517

518

519

520 521

522

523 524

525 526

527

528

529

530

- 509 Alicandro G, La Vecchia C, Islam N, Pizzato M. 2023. A comprehensive analysis of all-cause 510 and cause-specific excess deaths in 30 countries during 2020. Eur J Epidemiol. 511 doi:10.1007/s10654-023-01044-x
- 512 Centers for Disease Control and Prevention. 2023. COVID Data Tracker.
- 513 https://covid.cdc.gov/covid-data-tracker/
- 514 Centers for Disease Control and Prevention. 2023. COVID-19 serology surveillance. 515 https://www.cdc.gov/coronavirus/2019-ncov/covid-data/serology.html
 - Centers for Disease Control and Prevention. 2022. Weekly United States COVID-19 cases and deaths by state - ARCHIVED.
 - Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. 2022. Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol
 - COVID-19 Forecasting Team. 2022. Variation in the COVID-19 infection-fatality ratio by age. time, and geography during the pre-vaccine era: a systematic analysis. Lancet 399:1469-
 - Dagher H, Chaftari A-M, Subbiah IM, Malek AE, Jiang Y, Lamie P, Granwehr B, John T, Yepez E, Borjan J, Reyes-Gibby C, Flores M, Khawaja F, Pande M, Ali N, Rojo R, Karp DD, Chaftari P, Hachem R, Raad II. 2023. Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. Elife 12. doi:10.7554/eLife.81182
 - Di Felice G, Visci G, Teglia F, Angelini M, Boffetta P. 2022. Effect of cancer on outcome of COVID-19 patients: a systematic review and meta-analysis of studies of unvaccinated patients. Elife 11. doi:10.7554/eLife.74634
- Doan C, Li S, Goodwin JS. 2023. Breast and Lung Cancer Screening Among Medicare 532 Enrollees During the COVID-19 Pandemic. JAMA Netw Open 6:e2255589.
- 533 Fernandes GA, Junior APN, Azevedo E Silva G, Feriani D, França E Silva ILA, Caruso P, 534 Curado MP. 2021. Excess mortality by specific causes of deaths in the city of São Paulo, Brazil, during the COVID-19 pandemic. PLoS One 16:e0252238. 535
- Gobiņa I, Avotiņš A, Kojalo U, Strēle I, Pildava S, Villeruša A, Briģis Ģ. 2022. Excess mortality 536

associated with the COVID-19 pandemic in Latvia: a population-level analysis of all-cause and noncommunicable disease deaths in 2020. *BMC Public Health* **22**:1109.

- Grande E, Fedeli U, Pappagallo M, Crialesi R, Marchetti S, Minelli G, Iavarone I, Frova L, Onder G, Grippo F. 2022. Variation in Cause-Specific Mortality Rates in Italy during the First Wave of the COVID-19 Pandemic: A Study Based on Nationwide Data. *Int J Environ Res Public Health* **19**. doi:10.3390/ijerph19020805
- Han S, Zhuang Q, Chiang J, Tan SH, Chua GWY, Xie C, Chua MLK, Soon YY, Yang VS. 2022. Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. *BMJ Open* **12**:e044661.
- Han X, Hu X, Zhao J, Jemal A, Yabroff KR. 2022. Identification of Deaths Caused by Cancer and COVID-19 in the US During March to December 2020. *JAMA Oncol* **8**:1696–1698.
- Han X, Yang NN, Nogueira L, Jiang C, Wagle NS, Zhao J, Shi KS, Fan Q, Schafer E, Yabroff KR, Jemal A. 2023. Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment. *Lancet Oncol* 24:855–867.
- Haribhai S, Bhatia K, Shahmanesh M. 2023. Global elective breast- and colorectal cancer surgery performance backlogs, attributable mortality and implemented health system responses during the COVID-19 pandemic: A scoping review. *PLOS Glob Public Health* **3**:e0001413.
- Kontopantelis E, Mamas MA, Webb RT, Castro A, Rutter MK, Gale CP, Ashcroft DM, Pierce M, Abel KM, Price G, Faivre-Finn C, Van Spall HGC, Graham MM, Morciano M, Martin GP, Sutton M, Doran T. 2022. Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study. *PLoS Med* **19**:e1003904.
- Lee R, Xu W, Dozier M, McQuillan R, Theodoratou E, Figueroa J, UNCOVER and the International Partnership for Resilience in Cancer Systems (I-PaRCS), Breast Cancer Working Group 2. 2023. A rapid review on the COVID-19's global impact on breast cancer screening participation rates and volumes from January-December 2020. *Elife* 12. doi:10.7554/eLife.85680
- Lee W-E, Woo Park S, Weinberger DM, Olson D, Simonsen L, Grenfell BT, Viboud C. 2023. Direct and indirect mortality impacts of the COVID-19 pandemic in the United States, March 1, 2020 to January 1, 2022. *Elife* **12**. doi:10.7554/eLife.77562
- Lemanska A, Andrews C, Fisher L, Bacon S, Frampton AE, Mehrkar A, Inglesby P, Davy S, Roberts K, Patalay P, Goldacre B, MacKenna B, OpenSAFELY Collaborative, Walker AJ. 2023. Healthcare in England was affected by the COVID-19 pandemic across the pancreatic cancer pathway: A cohort study using OpenSAFELY-TPP. *Elife* 12. doi:10.7554/eLife.85332
- Lundberg CE, Santosa A, Björk J, Brandén M, Cronie O, Lindgren M, Edqvist J, Åberg M, Adiels M, Rosengren A. 2023. Age and sex differences in cause-specific excess mortality and years of life lost associated with COVID-19 infection in the Swedish population. *Eur J Public Health*. doi:10.1093/eurpub/ckad086
- Nascimento de Lima P, van den Puttelaar R, Hahn AI, Harlass M, Collier N, Ozik J, Zauber AG, Lansdorp-Vogelaar I, Rutter CM. 2023. Projected long-term effects of colorectal cancer screening disruptions following the COVID-19 pandemic. *Elife* **12**. doi:10.7554/eLife.85264
- National Cancer Institute. n.d. Cancer stat facts. SEER. https://seer.cancer.gov/statfacts/
- Nickson C, Smith MA, Feletto E, Velentzis LS, Broun K, Deij S, Grogan P, Hall M, He E, St John DJ, Lew J-B, Procopio P, Simms KT, Worthington J, Mann GB, Canfell K. 2023. A modelled evaluation of the impact of COVID-19 on breast, bowel, and cervical cancer screening programmes in Australia. *Elife* 12. doi:10.7554/eLife.82818
- Nonboe MH, Napolitano G, Schroll JB, Vejborg I, Waldstrøm M, Lynge E. 2023. Impact of COVID-19 pandemic on breast and cervical cancer screening in Denmark: A register-based

study. Elife 12. doi:10.7554/eLife.81605

- Raad II, Hachem R, Masayuki N, Datoguia T, Dagher H, Jiang Y, Subbiah V, Siddiqui B, Bayle A, Somer R, Fernández Cruz A, Gorak E, Bhinder A, Mori N, Hamerschlak N, Shelanski S, Dragovich T, Vong Kiat YE, Fakhreddine S, Pierre AH, Chemaly RF, Mulanovich V, Adachi J, Borjan J, Khawaja F, Granwehr B, John T, Yepez EY, Torres HA, Ammakkanavar NR, Yibirin M, Reyes-Gibby CC, Pande M, Ali N, Rojo RD, Ali SM, Deeba RE, Chaftari P, Matsuo T, Ishikawa K, Hasegawa R, Aguado-Noya R, García AG, Puchol CT, Lee DG, Slavin M, Teh B, Arias CA, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, Kontoyiannis DP, Malek AE, Chaftari A-M. 2023. International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship. *Elife* 12. doi:10.7554/eLife.81127
- Rüthrich MM, Giessen-Jung C, Borgmann S, Classen AY, Dolff S, Grüner B, Hanses F, Isberner N, Köhler P, Lanznaster J, Merle U, Nadalin S, Piepel C, Schneider J, Schons M, Strauss R, Tometten L, Vehreschild JJ, von Lilienfeld-Toal M, Beutel G, Wille K, LEOSS Study Group. 2021. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. *Ann Hematol* **100**:383–393.
- Seneviratne SL, Yasawardene P, Wijerathne W, Somawardana B. 2022. COVID-19 vaccination in cancer patients: a narrative review. *J Int Med Res* **50**:3000605221086155.
- Short KR, Kedzierska K, van de Sandt CE. 2018. Back to the Future: Lessons Learned From the 1918 Influenza Pandemic. *Front Cell Infect Microbiol* **8**:343.
- Silversmit G, Verdoodt F, Van Damme N, De Schutter H, Van Eycken L. 2021. Excess Mortality in a Nationwide Cohort of Cancer Patients during the Initial Phase of the COVID-19 Pandemic in Belgium. *Cancer Epidemiol Biomarkers Prev* **30**:1615–1619.
- Stadlbauer D, Tan J, Jiang K, Hernandez MM, Fabre S, Amanat F, Teo C, Arunkumar GA, McMahon M, Capuano C, Twyman K, Jhang J, Nowak MD, Simon V, Sordillo EM, van Bakel H, Krammer F. 2021. Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City. *Nature* **590**:146–150.
- Starkey T, Ionescu MC, Tilby M, Little M, Burke E, Fittall MW, Khan S, Liu JKH, Platt JR, Mew R, Tripathy AR, Watts I, Williams ST, Appanna N, Al-Hajji Y, Barnard M, Benny L, Burnett A, Bytyci J, Cattell EL, Cheng V, Clark JJ, Eastlake L, Gerrand K, Ghafoor Q, Grumett S, Harper-Wynne C, Kahn R, Lee AJX, Lomas O, Lydon A, Mckenzie H, NCRI Consumer Forum, Panneerselvam H, Pascoe JS, Patel G, Patel V, Potter VA, Randle A, Rigg AS, Robinson TM, Roylance R, Roques TW, Rozmanowski S, Roux RL, Shah K, Sheehan R, Sintler M, Swarup S, Taylor H, Tillett T, Tuthill M, Williams S, Ying Y, Beggs A, Iveson T, Lee SM, Middleton G, Middleton M, Protheroe A, Fowler T, Johnson P, Lee LYW. 2023. A population-scale temporal case-control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP). *Sci Rep* 13:11327.
- Tope P, Farah E, Ali R, El-Zein M, Miller WH, Franco EL. 2023. The impact of lag time to cancer diagnosis and treatment on clinical outcomes prior to the COVID-19 pandemic: A scoping review of systematic reviews and meta-analyses. *Elife* 12. doi:10.7554/eLife.81354
- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. 2020. Factors associated with COVID-19-related death using OpenSAFELY. *Nature* **584**:430–436.
- Yeh H-C, Golozar A, Brancati FL. 2018. Cancer and Diabetes In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US).

Table 1. Each diagnosis group and its corresponding ICD-10 codes, number of underlying deaths, mean age in years at time of death, the percentage of deaths occurring at home, and the percentage of deaths occurring in nursing homes for 2019 and 2020.

Year	Diagnosis Group	ICD-10 Codes	No. Deaths	Mean age, years (IQR)	%Home/ER	%Nursing Home
2019	Cancer	C00-C99	493,397	72 (64-81)	45	12
	Pancreatic Cancer	C25	37,864	72 (64-80)	51	9
	Colorectal Cancer	C18-C20	42,484	71 (61-82)	46	13
	Hematologic Cancers	C81-C96	47, 174	74 (67-84)	35	11
	Diabetes	E10-E14	70,763	72 (63-82)	53	17
	Alzheimer's	G30	98,675	87 (82-92)	29	50
2020	Cancer	C00-C99	513,275	72 (64-81)	55	8
	Pancreatic Cancer	C25	39,893	72 (65-80)	61	6
	Colorectal Cancer	C18-C20	43,990	71 (61-82)	56	9
	Hematologic Cancers	C81-C96	49, 161	74 (67-84)	46	8
	Diabetes	E10-E14	88,124	71 (62-82)	58	15
	Alzheimer's	G30	115,256	86 (82-92)	33	46

Table 2. The estimated number of excess deaths and the percentage over baseline for each diagnosis group when listed as both the underlying cause or anywhere on the death certificate (multiple cause). Estimates for the national-level data are provided for the full pandemic period and for each state based on when the first large wave was experienced.

			Multipl	e Cause	Underlying Cause		
Cause of Death	State	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline	
Cancer	National	Overall	12371*	2.0	-523	0.0	
	New York	1	924*	8.0	-313	-3.0	
	Texas	2	388	3.0	-97	-1.0	
	California	3	396	3.0	57	0.0	
Pancreatic Cancer	National	Overall	-122	0.0	-407	-1.0	
	New York	1	5	1.0	-18	-2.0	
	Texas	2	-3	0.0	-9	-1.0	
	California	3	1	0.0	-10	-1.0	
Colorectal Cancer	National	Overall	1242	3.0	223	1.0	
	New York	1	89	8.0	-4	0.0	
	Texas	2	27	2.0	-32	-3.0	
	California	3	-24	-2.0	-29	-3.0	
Hematologic Cancers	National	Overall	3068*	5.0	-235	-1.0	
	New York	1	163	13.0	-68	-7.0	
	Texas	2	153	12.0	46	4.0	
	California	3	25	2.0	-45	-4.0	
Diabetes	National	Overall	85717*	39.0	11398*	17.0	
	New York	1	6120*	126.0	549*	35.0	
	Texas	2	4587*	76.0	411*	22.0	
	California	3	3056*	49.0	435*	23.0	
Alzheimer's	National	Overall	32238*	31.0	18472*	21.0	
	New York	1	825*	55.0	260	22.0	
	Texas	2	1756*	65.0	1156*	51.0	
	California	3	927*	25.0	493*	16.0	

^{*}Confidence interval does not include zero

Table 3. Projections of COVID-19-related excess mortality patterns for different cancers and chronic conditions in the US, under different hypotheses for the association between the condition and COVID-19. Projections are provided for the null hypothesis of no biological interaction between the condition and COVID-19; these projection are solely driven by the size and age distribution of the population living with each condition (where age determines the infection-fatality ratio from COVID-19), and the baseline risk of death from the condition over a similar time period (March to December 2019, 10 months). Additional projections are provided under alternative hypotheses, where each condition is associated with a relative risk (RR) of 2 for COVID-19 related death (infection-fatality ratio multiplied by 2).

Causes of Death	Estimated no. of US individuals living with condition	Ratio of 2019 deaths (Mar- Dec) to estimat ed populat ion at risk (baseli ne risk of death)	Estimated % of population with condition aged ≥ 65 years	Expected no. of excess deaths, Mar-Dec 2020 if condition is not associated with COVID-19 (null hypothesis, RR=1)	Expected % elevation* in mortality over baseline, Mar-Dec 2020, if condition is not associated with COVID-19 (null hypothesis, RR=1)	Expected % elevation* in mortality over baseline, Mar-Dec 2020, if condition has a RR of 2 for COVID-19 death	Estimated % mortality* elevation over baseline in 2020 US vital statistics (estimates from Table 2) (95%Ci)
Cancer (all)	18000000	1:32.9	58%	36823	7%	13%	2% (1 - 4%)
Pancreatic cancer	90000	1:2.3	69%	214	1%	1%	0% (-7 - 7%)
Lung cancer	541000	1:4.4	71%	1317	1%	2%	1% (-3 - 5%)
Colorectal cancer	1545000	1:31.5	56%	2829	6%	12%	3% (-3 - 9%)
Breast cancer	3800000	1:87.3	48%	6201	14%	28%	2% (-4 - 9%)
Hematological cancer	550000	1:9.5	63%	1430	2%	5%	5% (0 - 12%)
Diabetes	34200000	1:149.1	42%	64802	28%	57%	39% (33 - 45%)
Alzheimer's	6500000	1:54.6	100%	54345	46%	91%	31% (22 - 42%)

* % elevation calculated as expected no of excess deaths in the pandemic under the null hypothesis of no biological association between cancer and COVID-19 (column 5) divided by expected deaths in a non-pandemic period, which are based on baseline risk of death and population size (column 2 multiplied by column 3).

Figure 1. Weekly counts of death certificates listing COVID-19 as either the underlying or a multiple cause. When included on a death certificate, COVID-19 was most often listed as the underlying cause of death rather than a contributing cause. National-level data reveal three distinct waves: Wave 1 (spring, March 1 - June 27, 2020), Wave 2 (summer, June 28 - October 3, 2020), and Wave 3 (winter, October 4 - December 6, 2020, incomplete). Vertical dashed lines represent the peak of each wave, dotted lines represent the number of reported cases (y-axis on the right). New York experienced its first large COVID-19 wave in Wave 1, while Texas had its first large wave in Wave 2 and California did not experience a large wave until Wave 3 which had not yet peaked at the end of 2020.




Figure 2. National-level weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or anywhere on the death certificate (multiple cause) from 2014 to 2020. Baselines during the pandemic are projected based on the previous years of data.

National




Figure 3. The same as figure 1, but for New York. New York experienced its first large wave of COVID-19 in spring 2020 (Wave 1).

New York




Figure 4. The same as figure 1, but for Texas. Texas experienced its first large wave of COVID-19 in the summer of 2020 (Wave 2).

Texas





Figure 5. The same as figure 1, but for California. California did not experience a large wave of COVID-19 until the winter of 2020-2021 (Wave 3), only the first half of which is captured here.

California



APPENDIX 1 Supplemental Methods

Characteristics of cancer, diabetes, and Alzheimer's deaths in the pre-pandemic period.

For each chronic condition studied (cancer, diabetes, IHD, Alzheimer's), we assessed potential changes in the characteristics of deaths during the pandemic period that are unrelated to timing but may signal an association with COVID-19. For instance, age is known to be a major risk factor for COVID-19 mortality. For each chronic condition, we computed the average age-at-death in the pre-pandemic year 2019 and compared this to the average age-at-death in 2020. The second potential confounder is living arrangement, as individuals living in nursing homes may be at increased risk of exposure (and death) to COVID-19 due to mixing, even though their underlying condition is not per se a risk factor. To test this hypothesis, we also compared the proportion of individuals in each disease group who died in nursing homes in 2019 and 2020. And finally, to illustrate the impact of coding practices we compared ICD-10 letter categories between 2020 and 2019 for the underlying cause of death when cancer or diabetes are included on the death certificate, but are not listed as the underlying cause of death (Appendix 1 - Figure 9). For 2020, we further compared death certificates listing both COVID-19 and cancer to those listing both COVID-19 and diabetes. For all comparisons between 2019 and 2020 data are limited to March to December to isolate the pandemic period.

Supplemental tables and figures

Appendix 1 - Table 1. Diagnosis groups and corresponding ICD-10 codes, number of underlying and multiple cause deaths, mean age in years at time of death, the percentage of deaths occurring at home, and the percentage of deaths occurring in nursing homes for 2019 and 2020.

				Underly	ing Cause		Multiple Cause			
Year	Diagnosis group	ICD-10 codes	No. Deaths	Mean age, years (IQR)	%Home/E R	%Nursing Home	No. Deaths	Mean age, years (IQR)	%Home/E R	%Nursing Home
2019	Cancer	C00-C99	493,397	72 (64-81)	45	12	546,453	72 (64-82)	44	13
	Pancreatic Cancer	C25	37,864	72 (64-80)	51	9	39,798	72 (64-80)	50	9
	Lung Cancer	C34	114,552	72 (65-80)	45	12	123,622	72 (65-80)	44	12
	Colorectal Cancer	C18-C20	42,484	71 (61-82)	46	13	49,053	72 (62-83)	45	14
	Breast Cancer	C50	35,115	69 (59-81)	44	13	43,519	71 (61-83)	43	15
	Hematological Cancer	C81-C96	47,174	74 (67-84)	35	11	57,892	74 (67-84)	35	12
	Diabetes	E10-E14	70,763	72 (63-82)	53	17	229,326	74 (65-84)	46	19
	Alzheimer's	G30	98,675	87 (82-92)	29	50	118,993	87 (82-92)	29	48
	Ischemic Heart Disease	120-125	292,659	77 (67-88)	50	18	440,225	77 (68-87)	47	18
	Kidney Disease	N00-07, 17- 19,25-28	46,120	76 (68-87)	25	18	189,938	76 (67-87)	20	15

2020	Cancer	C00-C99	513,275	72 (64-81)	55	8	586,503	72 (64-82)	52	9
	Pancreatic Cancer	C25	39,893	72 (65-80)	61	6	42,383	72 (65-80)	60	6
	Lung Cancer	C34	115,554	72 (65-80)	54	8	127,671	72 (65-80)	53	8
	Colorectal Cancer	C18-C20	43,990	71 (61-82)	56	9	52,319	72 (62-83)	53	10
	Breast Cancer	C50	36,296	70 (60-81)	54	10	47,094	72 (62-83)	51	12
	Hematological Cancer	C81-C96	49,161	74 (67-84)	46	8	64,840	74 (68-84)	43	9
	Diabetes	E10-E14	88,124	71 (62-82)	58	15	343,061	73 (65-83)	45	16
	Alzheimer's	G30	115,256	86 (82-92)	33	46	151,206	86 (82-92)	31	47
	Ischemic Heart Disease	120-125	327,854	76 (67-88)	54	16	533,204	77 (68-87)	49	16
	Kidney Disease	N00-07, 17- 19,25-28	49,796	76 (68-87)	30	15	255,708	75 (67-86)	21	12

Appendix 1 - Table 2. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each diagnosis group (National). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

		Multip	le Cause	Unde	rlying Cause
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline
Cancer	Overall	12371*	2.0	-523	-0.0
	1	2930	1.0	-1685	-1.0
	2	5165*	3.0	1557	1.0
	3	4275*	3.0	-395	-0.0
Pancreatic Cancer	Overall	-122	-0.0	-407	-1.0
	1	-125	-1.0	-222	-1.0
	2	-72	-1.0	-156	-1.0
	3	75	1.0	-28	-0.0
Lung Cancer	Overall	700	1.0	-1086	-1.0
	1	-174	-0.0	-743	-2.0
	2	481	1.0	-15	-0.0
	3	392	1.0	-328	-1.0
Breast Cancer	Overall	821	2.0	-681	-2.0
	1	272	2.0	-281	-2.0
	2	350	2.0	-75	-1.0
	3	200	2.0	-326	-4.0
Colorectal Cancer	Overall	1242	3.0	223	1.0
	1	186	1.0	-144	-1.0
	2	456	3.0	165	1.0
	3	600	5.0	201	2.0
Hematological Cancers	Overall	3068*	5.0	-235	-1.0
	1	884	4.0	-195	-1.0
	2	1121*	6.0	178	1.0
	3	1063*	8.0	-218	-2.0
Diabetes	Overall	85717*	39.0	11398*	17.0

	1	31301*	33.0	4147*	14.0	
	2	28692*	40.0	4466*	20.0	
	3	25724*	46.0	2785*	16.0	
Alzheimer's	Overall	32238*	31.0	18472*	21.0	
	1	11793*	27.0	6801*	19.0	
	2	10992*	33.0	7081*	26.0	
	3	9452*	35.0	4591*	21.0	
Ischemic Heart Disease	Overall	65239*	16.0	24044*	9.0	
	1	23607*	13.0	9487*	8.0	
	2	23699*	18.0	9983*	11.0	
	3	17934*	17.0	4574*	7.0	
Kidney Disease	Overall	45702*	25.0	1385	3.0	
	1	13697*	18.0	203	1.0	
	2	16148*	28.0	969*	7.0	
	3	15857*	34.0	213	2.0	

^{*}Confidence interval does not include zero

Appendix 1 - Table 3. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each diagnosis group (New York). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

		Multip	le Cause	Unde	rlying Cause
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline
Cancer	Overall	1226	4.0	-270	-1.0
	1	924*	8.0	-313	-3.0
	2	159	2.0	71	1.0
	3	142	2.0	-27	-0.0
Pancreatic Cancer	Overall	-55	-2.0	-73	-3.0
	1	5	1.0	-18	-2.0
	2	-13	-2.0	-16	-2.0
	3	-47	-8.0	-38	-7.0
Lung Cancer	Overall	89	1.0	-108	-2.0
	1	58	2.0	-113	-5.0
	2	33	2.0	33	2.0
	3	-2	-0.0	-28	-2.0
Breast Cancer	Overall	173	7.0	-14	-1.0
	1	155	15.0	-15	-2.0
	2	15	2.0	11	2.0
	3	3	0.0	-11	-2.0
Colorectal Cancer	Overall	172	7.0	78	4.0
	1	89	8.0	-4	-0.0
	2	34	4.0	40	6.0
	3	49	8.0	42	8.0
lematological Cancers	Overall	245	8.0	-53	-2.0
	1	163	13.0	-68	-7.0
	2	30	3.0	9	1.0
	3	52	7.0	6	1.0
Diabetes	Overall	7180*	63.0	624	17.0

	1	6120*	126.0	549*	35.0
	2	560*	15.0	26	2.0
	3	500*	17.0	50	5.0
Alzheimer's	Overall	923*	26.0	265	10.0
	1	825*	55.0	260	22.0
	2	-8	-1.0	-6	-1.0
	3	106	11.0	11	2.0
Ischemic Heart Disease	Overall	7133*	24.0	3874*	17.0
	1	7054*	56.0	4473*	47.0
	2	84	1.0	-224	-3.0
	3	-5	-0.0	-374	-6.0
Kidney Disease	Overall	2302*	30.0	-29	-1.0
	1	2004*	62.0	23	3.0
	2	76	3.0	-46	-7.0
	3	222	11.0	-6	-1.0

^{*}Confidence interval does not include zero

. Appendix 1 - Table 4. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each diagnosis group (Texas). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

		Multip	le Cause	Unde	rlying Cause	
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline	
Cancer	Overall	480	1.0	-421	-1.0	
	1	-21	-0.0	-109	-1.0	
	2	388	3.0	-97	-1.0	
	3	113	1.0	-215	-3.0	
Pancreatic Cancer	Overall	-48	-2.0	-79	-3.0	
	1	-48	-4.0	-59	-6.0	
	2	-3	-0.0	-9	-1.0	
	3	3	0.0	-11	-2.0	
Lung Cancer	Overall	55	1.0	-48	-1.0	
	1	4	0.0	-11	-0.0	
	2	11	0.0	-33	-1.0	
	3	40	2.0	-4	-0.0	
Breast Cancer	Overall	-48	-2.0	-151	-6.0	
	1	-59	-5.0	-58	-6.0	
	2	16	2.0	-35	-4.0	
	3	-4	-1.0	-58	-9.0	
Colorectal Cancer	Overall	59	2.0	-81	-3.0	
	1	-3	-0.0	-40	-3.0	
	2	27	2.0	-32	-3.0	
	3	35	4.0	-9	-1.0	
Hematological Cancers	Overall	253	7.0	68	2.0	
	1	56	4.0	34	3.0	
	2	153	12.0	46	4.0	
	3	45	5.0	-12	-2.0	
Diabetes	Overall	8930*	48.0	623	11.0	

	1	1559*	20.0	107	5.0
	2	4587*	76.0	411*	22.0
	3	2785*	58.0	105	7.0
Alzheimer's	Overall	3373*	39.0	2278*	32.0
	1	736*	20.0	593*	20.0
	2	1756*	65.0	1156*	51.0
	3	880*	40.0	529*	29.0
Ischemic Heart Disease	Overall	5188*	16.0	1899*	10.0
	1	721	5.0	314	4.0
	2	3037*	29.0	1262*	20.0
	3	1431*	17.0	323	6.0
Kidney Disease	Overall	5789*	37.0	321	9.0
	1	716*	11.0	63	4.0
	2	3184*	64.0	189	17.0
	3	1890*	48.0	70	8.0

^{*}Confidence interval does not include zero

Appendix 1 - Table 5. Supplemental Table 2. Estimated number of excess deaths and the percentage over baseline for each diagnosis group (California). Estimates are aggregated over all of 2020 and for each COVID-19 wave during 2020.

		Multip	le Cause	Unde	rlying Cause	
Cause of death	Wave	Excess Deaths	% Over Baseline	Excess Deaths	% Over Baseline	
Cancer	Overall	1135	2.0	220	0.0	
	1	216	1.0	44	0.0	
	2	523	3.0	119	1.0	
	3	396	3.0	57	0.0	
Pancreatic Cancer	Overall	-92	-2.0	-102	-3.0	
	1	-14	-1.0	-18	-1.0	
	2	-79	-6.0	-74	-6.0	
	3	1	0.0	-10	-1.0	
ung Cancer	Overall	120	1.0	14	0.0	
	1	21	1.0	0	0.0	
	2	44	2.0	-16	-1.0	
	3	54	3.0	30	2.0	
Breast Cancer	Overall	58	1.0	-55	-2.0	
	1	-27	-1.0	-31	-2.0	
	2	82	6.0	26	2.0	
	3	3	0.0	-49	-5.0	
Colorectal Cancer	Overall	-36	-1.0	-71	-2.0	
	1	-21	-1.0	-25	-1.0	
	2	8	0.0	-17	-1.0	
	3	-24	-2.0	-29	-3.0	
Hematological Cancers	Overall	100	2.0	-84	-2.0	
	1	-5	-0.0	-34	-2.0	
	2	80	4.0	-5	-0.0	
	3	25	2.0	-45	-4.0	

Diabetes	Overall	9353*	37.0	1444*	20.0
	1	2403*	22.0	394	12.0
	2	3894*	49.0	616*	27.0
	3	3056*	49.0	435*	23.0
Alzheimer's	Overall	3495*	23.0	1879*	15.0
	1	1096*	17.0	552	10.0
	2	1472*	31.0	833*	21.0
	3	927*	25.0	493*	16.0
Ischemic Heart Disease	Overall	6326*	16.0	3187*	12.0
	1	1591*	9.0	750	6.0
	2	3072*	25.0	1656*	20.0
	3	1663*	17.0	781*	12.0
Kidney Disease	Overall	4579*	25.0	239	7.0
	1	914*	11.0	25	2.0
	2	2209*	38.0	143	14.0
	3	1455*	32.0	72	9.0

^{*}Confidence interval does not include zero

Appendix 1 - Table 6. Projections of COVID-19-related excess mortality patterns for all cancers, ischemic heart disease, and kidney disease in the US, under different hypotheses for the association between the condition and COVID-19.

Causes of Death	Estimat ed no. of US individu als living with conditio n	Ratio of 2019 deaths to estima ted popula tion at risk	Estima ted % of popula tion with conditi on aged ≥ 65 years	Expect ed no. of excess deaths	Expected % COVID-19 mortality elevation over baseline if condition is not associate d with COVID-19 (null hypothesi s, RR=1)	Expected % COVID- 19 mortality elevation over baseline if condition has a RR of 2 for COVID-19 death	Expected % COVID-19 mortality elevation over baseline if condition has a RR of 5 for COVID-19 death	Estimated % COVID-19 mortality elevation over baseline in 2020 US vital statistics (observations from Table 2) (95%Ci)
Cancer (all)	18000000	1:32.9	58%	36823	7%	13%	34%	2% (1 - 4%)
Diabetes	34200000	1:149.1	42%	64802	28%	57%	141%	39% (33 - 45%)
Alzheimer's	6500000	1:54.6	100%	54345	46%	91%	228%	31% (22 - 42%)
Ischemic Heart Disease	20000000	1:45.4	63%	70267	16%	32%	80%	16% (10 - 21%)
Kidney Disease	37000000	1:194.8	56%	95380	50%	100%	251%	25% (19 - 33%)

Appendix 1 - Table 7. Estimated age distributions and age-adjusted infection fatality ratios for six types of cancer, diabetes, Alzheimer's, IHD, and kidney disease. For each condition we estimated an age-adjusted infection fatality ratio. We first determined the approximate proportion of persons living with each condition across several broad age groups. We aimed to keep age groups roughly consistent between conditions, with the exception of Alzheimer's disease for which the entire population at risk is ≥65 years. For all-cause cancer, pancreatic, lung, colorectal, and breast we used the age distribution of newly diagnosed cases in 2019. We then took a weighted average of the age-specific infection fatality ratios, using the midpoint for each age group. For the oldest age group we used the infection fatality ratio for the average age-at-death in 2019 for that condition.

Condition	Age group	Estimated Proportion	Midpoint age (years)	Age-specific infection fatality ratio
All-cause cancer ^a	<15 years	.01	7	0.1123
All cause carreer	15 - 44 years	.07	30	0.0573
	45 - 64 years	.35	55	0.6242
	65+ years	.58	72	3.5527
	Weighted	.00	12	2.272999
Pancreatic cancer ^a	<45 years	0.02	22	0.0188
andreatic cancer	45-64 years	0.28	55	0.6242
	65+ years	0.69	72	3.5527
	Weighted	0.00	12	2.636392
Lung cancer ^a	<45	0.01	22	0.0188
Lung Gunder	45-64	0.28	55	0.6242
	65+	0.71	72	3.5527
	Weighted	0.71	12	2.703841
Colorectal cancer ^a	<45	0.07	22	0.0188
<u> </u>	45-64	0.37	55	0.6242
	65+	0.56	71	3.2022
	Weighted	0.50	7 1	2.034357
Breast cancer ^a	<45	0.09	22	0.0188
Breast caricer	45-64	0.42	55	0.6242
	65+	0.48	71	3.2022
	Weighted	0.10	, ,	1.813096
Hematological cancers b		0.02	7	0.0023
nomatological cancers	15-39 years	0.08	27	0.0386
	40-64 years	.27	52	0.4958
	65+ years	.63	74	4.3679
	Weighted		, .	2.888777
Diabetes ^c	<45	0.14	22	0.0188
	54-64	0.43	55	0.6242
	65+	0.42	74	4.3679
	Weighted	0.12	, ,	2.105315
Alzheimer's ^d	65-74	0.27	70	2.8851
AIZHEIIHEI S	75-84	0.37	80	8.0093
	85+	0.36	87	15.5984
	Weighted	0.00	07	9.289791
Ischemic heart disease e	<45	0.06	22	0.0188
iconomic meant disease	45-64	0.31	55	0.6242
	45-04 65+	0.63	77	5.932
	Weighted			3.903738
Kidney disease ^f	<45	0.17	22	0.0188
itidiley disease	45-64	0.17	55	0.6242
	65+	0.56	75	4.8397
	Weighted		1.0	2.864266

^a Centers for Disease Control and Prevention. United States Cancer Statistics: Data Visualizations.


[&]quot;Leading Cancers by Age, Sex, Race and Ethnicity." Retrieved on 03 October 2023 from: https://gis.cdc.gov/Cancer/USCS/#/Demographics/

39


- ^b Centers for Disease Control and Prevention. United States Cancer Statistics. "Hematological Cancer Incidence, Survival, and Prevalence." Retrieved on 03 October 2023 from:
- https://www.cdc.gov/cancer/uscs/about/data-briefs/no30-hematologic-incidence-surv-prev.htm
- ^c Centers for Disease Control and Prevention. "National Diabetes Statistics Report 2020." Retrieved on 03 October 2023 from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
- ^d Alzheimer's Association. "2023 Alzheimer's Disease Facts and Flgures: Special Report." Retrieved on 03 October 2023 from: https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
- ° Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report. "QuickStats: Percentage* of Adults Aged ≥18 Years with Diagnosed Heart Disease,† by Urbanization Level§ and Age Group National Health Interview Survey, United States, 2020." Retrieved on 03 October 2023 from: https://www.cdc.gov/mmwr/volumes/71/wr/mm7123a4.htm
- ^f Centers for Disease Control and Prevention. Chronic Kidney Disease Initiative. "Chronic Kidney Disease in the United States, 2023." Retrieved on 03 October 2023 from: https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html#:~:text=According%20to%20current%20estimates%3A&text=CKD%20is%20more%20common%20in,%25)%20than%20 men%20(12%25)

Appendix 1 - Figure 1. National-level weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or anywhere on the death certificate (multiple cause) from 2017 to 2020. Baselines during the pandemic are projected based on the previous years of data.


National




Appendix 1 - Figure 2. Correlation between weekly number of COVID-19 coded deaths and excess underlying deaths for each diagnosis group (National).




Appendix 1 - Figure 3. Correlation between weekly number of COVID-19 coded deaths and excess multiple cause deaths for each diagnosis group (National).



Appendix 1 - Figure 4. Correlation between weekly number of COVID-19 coded deaths and excess underlying deaths for each diagnosis group (New York).




Appendix 1 - Figure 5. Correlation between weekly number of COVID-19 coded deaths and excess underlying deaths for each diagnosis group (New York).




Appendix 1 - Figure 6. Weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or anywhere on the death certificate (multiple cause) from 2017 to 2020 in New York. Baselines during the pandemic are projected based on the previous years of data.

New York




Appendix 1 - Figure 7. Weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or anywhere on the death certificate (multiple cause) from 2017 to 2020 in Texas. Baselines during the pandemic are projected based on the previous years of data.

Texas



Appendix 1 - Figure 8. Weekly observed and estimated baseline mortality for each diagnosis group as both the underlying cause or anywhere on the death certificate (multiple cause) from 2017 to 2020 in New York. Baselines during the pandemic are projected based on the previous years of data.

California



Appendix 1 - Figure 9. Comparison of ICD-10 letter categories between 2020 and 2019 for the underlying cause of death when cancer or diabetes are included on the death certificate, but are not listed as the underlying cause of death. For both cancer and diabetes, I codes (diseases of the circulatory system) make up the majority of underlying deaths. The most notable difference between 2019 and 2020 is the increase in U codes, which includes COVID-19 (U071). In total there were 13,434 deaths ascribed to COVID-19 (UC deaths) among cancer MC deaths. COVID-19 was included in <3% of all cancer deaths and 17% of diabetes deaths. In both cases it was listed as the UC on the majority of death certificates where it was included (81% and 97% for cancer and diabetes, respectively).

